Back to results
US 10,501,526 B2Granted
Human antibodies to Ebola virus glycoprotein
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsChristos Kyratsous, William Olson, Peter Mason, Neil Stahl
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsChristos Kyratsous, William Olson, Peter Mason, Neil Stahl
Estimating the term…
The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
A method of treating or ameliorating at least one symptom of EBOV infection, or of decreasing the frequency or severity of at least one symptom of EBOV infection, the method comprising administering to a subject in need thereof at least one antibody or antigen-binding fragment thereof comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained within any one of the heavy chain variable region (HCVR) and light chain variable region (LCVR) amino acid sequence pairs selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.